Over the years, more and more information has been revealed into how the process of hemostasis works in the human body. The coagulation analyses performed in the clinical laboratory are of clinical importance for patients admitted to the stroke unit, the hematology ward, the intensive care and the surgical department.
Three projects are carried out in this thesis. In the first project there is investigated whether the TT can be introduced as a screening test for the presence of clinically relevant dabigatran concentrations in patients who are to receive thrombolysis. The normal range for the TT is also verified. In the second project, the quantitative assay of UFH concentration with specific calibration curve for UFH will be evaluated. It is verified that the LMWH calibration curve is also applicable for UFH determination. As a third and final project the sensitivity of aPTT reagent to LMWH and UFH is assessed.
This study is performed in the clinical laboratory of AZ Groeninge Kortrijk on the Sysmex CS-2500, Siemens Healthineers which is a fully automated blood coagulation instrument on which a variety of coagulation parameters can be analyzed. For the first project a spiking experiment is performed, with dilution of a dabigatran standard in normal pooled plasma. Additionally, patient samples with normal values are analyzed for verification of the normal range. For the second project citrate plasma samples from patients on ECMO are analyzed for UFH concentration using UFH and LMWH calibration curves. For the third project a spiking experiment is conducted by diluting three different heparin preparations in normal pooled plasma. In addition to analysis of these dilution series a retrospective analysis of aPTT and anti-Xa results of patient treated with Fraxiparine is conducted.
For the first project it may be decided that the TT is the most sensitive assay for the presence of dabigatran, it can be applied for the confirmation of the absence of dabigatran. The PT is the least sensitive method for detection of dabigatran. The aPTT shows an intermediate sensitivity for dabigatran. A further experiment with patient samples is required. It should be discussed with the neurology department which cut-off of dabigatran concentration is appropriate to administer thrombolysis. For the reference range verification of TT, it can be decided that the reference interval is from 14,6 to 19,6 seconds. The predefined reference values of the package notice are between 15 and 22 seconds. It can be concluded that the lower limit from the package notice can be applied, but the upper limit may need to be adjusted.
In the second experiment it is observed that for higher concentrations of UFH, the LMWH calibration curve may not be appropriate. Further research is required because this experiment is only performed on samples from two different patients, which does not provide a representative population of patients receiving UFH.
Finally it can be concluded that the aPTT is not an appropriate parameter for determining the LMWH concentration.
Overall, it can be concluded that this thesis already provides some valuable results for optimalization of coagulation testing. Further research on a larger scale is needed to apply these findings in the laboratory.
Introduction: The fastest possible diagnosis of invasive aspergillosis (IA) is essential as the earlier a patient receive the adequate therapy the higher his survival rate. Currently, the turnaround time of the galactomannan assay in AZ Groeninge is 3 days on average because the analysis is sent to an external lab where it is performed in batch.
Objectives: The goal of this study is to evaluate and compare the performances of two lateral flow devices (LFD) on stored samples from a large non university hospital without transplant unit.
Methodology: The study included 50 archived samples: 20 samples that were galactomannan (GM) positive (> 1.0 index), 20 were negative (<0.5 index) and 10 had borderline results (i.e. 0,5 - 1,0 index). In this experiment both the Sona LFA (IMMY) and the ASP LFD (OLM diagnostics) were performed as descripted by the manufacturer and compared to GM results. Both LFD were read out by using a digital cube reader.
Results: In our hands, both tests had a sensitivity of 100%.The specificity of the ASP LFD was 86,7% and of the Sona LFA 76,7% at the cutoff of 1.0. However it must be noted that through the sample selection, the obtained prevalence of IA is not representative for our centre. When the tests were compared using the McNemar’s test at a cut-off of 1,0 GM index the Sona LFA turned out to be significantly different from the GM standard, however the ASP FLD was not statistically different from the GM standard. At a cut-off of 0,5 GM index, both tests were not statistically different to the GM standard. The decision to pre-treat (or not to pre-treat) samples when using the ASP LFD resulted in subjective decisions.
Conclusions: Overall, it can be concluded that both LFD’s could replace the galactomannan test. However, more data is needed to support this.
Human immunoglobulin molecules consist of two identical heavy chains and identical light chains (kappa or lambda). There are five different classes: immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin E (IgE) and immunoglobulin D (IgD). Plasma cells are responsible for the production of antibodies/ immunoglobulins, which protect the body against infections, bacteria and tumors. Free light chains (FLC) are natural products of B lymphocytes and as such form a unique biomarker of neoplastic and reactive B cell-related disorders. Increased FLCs are associated with multiple myeloma, AL amyloidosis, smouldering multiple myeloma (SMM) and monoclonal gammopathy of unknown significance.
The aim is to determine whether the measurement of free light chains in serum, using the monoclonal assay with Siemens N Latex reagent, performs analytically at least equivalent to the currently used polyclonal test with the Freelite reagent from The Binding Site. And if so, whether this could lead to better practices with regard to screening and follow-up of monoclonal gammopathies. Antigen excess, where results are underestimated, is an important aspect because incorrect results can lead to missed diagnoses and incorrect follow-up of patients.
Both The Binding Site and Siemens fall within the established criteria for precision and accuracy. All parameters also meet at least the minimum predefined performance criteria for total error.
Method comparison reveals both reagents are neither statistically nor analytically transparent. Although there appears to be a very good association across the categories of reduced, normal and increased value, it is not possible to speak of clinically equivalent methods. The recovery experiment is a six-point serial dilution series made starting from a serum pool of different routine samples. For the Verification of the linearity in the low measuring range, based on the CLSI EP6 protocol. In conclusion, it can be stated that there is no evidence of antigen excess in assays with the Siemens reagent. According to the literature, the reagent from The Binding Site may be more susceptible to this phenomenon, although no hard evidence was found for this.
It appears that both the reagent from Siemens and the reagent from The Binding Site perform acceptable in terms of precision, accuracy and measurement uncertainty in on the Atellica NEPH 630. Linearity in the low measuring range can be assumed and for antigen excess, no clear evidence was found. In summary, it can be said that both reagents are suitable for routine analysis of free light chains lambda and kappa on the Atellica NEPH 630.
Abstract Bachelor Project 2 MLT 2018-2019: Evaluation of two phenotypical assays for the detection of carbapenemases
Carbapenems are potent broad-spectrum antibiotics which are being used in hospitals for the treatment of serious infections with multidrug-resistant bacteria. Resistance against carbapenems by production of carbapenemases in gram-negative bacteria is an increasing problem worldwide. Detection of carbapenemases in the routine microbiology laboratory however can be a challenge. Recently, multiplexed immunochromatographic assays (RESIST-4 O.K.N.V. and NG-Test CARBA 5) which allow rapid simultaneous detection and identification of multiple types of carbapenemases on bacterial isolates, have been developed.
The aim of this project is to evaluate two immunochromatographic assays for the detection and identification of the four respectively five most common types of carbapenemase enzymes (RESIST-4 O.K.N.V. and NG-Test CARBA 5).
Both assays were easy to perform and use of a small inoculum (1 µl) was sufficient for optimal test results. An impact on test performance of prolonged incubation or culture media type could not be demonstrated. Accuracy was evaluated using a collection of 51 well-characterized carbapenem-resistant isolates, including 30 carbapenemase producers. Perfect results were observed with both assays. Precision evaluation resulted also in 100 % reproducibility with both assays.
Review of the literature showed that the detection of class A and B carbapenemase is sensitive and specific for both assays. Regarding the detection type B carbapenemase, sensitivity is somewhat less, especially for IMP type, a very rare type in Belgium.
Based upon these characteristics, both assays have an added value for the microbiology laboratory when integrated in detection algorithms for carbapenemases.
The continuous improvement of the quality of the tests used in a medical context is an important aspect of modern, clinical laboratories. One of the ways of achieving this objective is by continuously (re)evaluating and improving the reagents used in the lab. This study therefore aims to compare and validate different reagents for various thrombophilia tests currently performed in the laboratory of AZ groeninge. The main objective of this study is to obtain an effective and reliable test for the detection of protein C, protein S and antithrombin deficiency and for the screening of haemostasis anomalies like activated protein C resistance (APCr). These tests are helpful for an accurate and effective treatment of thrombophilia patients and therefore they should be examined and tested in detail. Multiple firms, namely Siemens, Hyphen Biomed and Werfen offer reagents for the measurement of these four parameters in citrate plasma samples.
The validation of each reagent is achieved by determining the repeatability, reproducibility, bias and total error of each test. The various tests are also checked for the effect of possible interfering components like a highly haemolytic sample or the presence of the anaesthetic propofol in the citrate plasma. A method comparison is also performed between the different reagents. Finally a comparison is made of both the cost and shelf life of each reagent. All measurements are performed on the Sysmex CS2100i. After gathering the above mentioned data, the most optimal test will be recommended for usage in the laboratory of AZ groeninge.
The following results have been obtained:
The Werfen COAMATIC Protein C assay is the most recommended assay for the measurement of protein C levels in plasma. Both the total error and the precision have been determined to be the best of the three examined assays. In addition of this great performance, the shelf life of this test (three months at 2-8°C) is longer than the shelf life of any other examined reagent.
The INNOVANCE Free PS Ag assay of Siemens is the best choice for the evaluation of protein S. It shows great performance on the CS2100i and has other good characteristics like low cost and a decent shelf life.
For the detection of antithrombin deficiencies, the tests offered by Hyphen Biomed and Siemens are nearly equal in both performance and cost/shelf life.
Because of a continual calibration failure due to an unknown cause, the APCr assay of Hyphen has not been taken into account for the final choice of APCr test. The Siemens ProC Global test shows less false positive results and is less influenced by the presence of propofol in a patient’s blood. However, the performance of the ProC Ac R test is better than the ProC Global test. Therefore the laboratory itself should decide which of the two ProC assays has the most significant advantage when used in the lab.
Due to the limited availability of reagents and patient samples, the method comparison has only been performed on a low amount of samples. If possible the laboratory method comparison should be reperformed in the future on a higher amount of citrate plasma samples. It is also recommended to evaluate the reliability of the reference values and the cut off values mentioned in the leaflets of each company before applying them in the laboratory.
The aim of this research is to validate a new Autostainer Link 48 from the firm Agilent as replacement for the old platform. The aim of this research is to secure the correct sample staining before analysing analyse patient samples. The Autostainer Link 48 stains paraffin slides using immunohistochemistry. For this study, four parameters being tested: repeatability, reproducibility, correctness, homogeneity.
To test the repeatability, antibodies such as CD7, CK7, CD45, CK PAN, Ki67 being stained all together in one run, on three several days. There is one slide of every antibody in the run. That’s different with the reproducibility, there are three slides of every antibody being stained in one run. The antibodies being stained for reproducibility are the same as the ones stained for repeatability. Reproducibility is performed on one day, not on several days.
The correctness is examined by staining with antibodies such as PMS2, MLH1, MSH2, MSH6, CD117, S100, PDL-1, P53, BCL6 one time in a run. Last but not least there is the homogeneity as an examined parameter. Therefor, an antibody such as CK PAN or vimentin is placed in the staining platform on all 48 sites, to check if there is a homogeneous staining.
As a result of the study the four parameters were approved by the pathologists. At the end of the study, because all parameters were approved, the Autostainer was released for analysing patient samples. The validation process was carried out before the old Autostainer was removed
Validation of procalcitonin analyses. The three kits (Vidas Brahms PCT, Elecsys Brahms PCT, and PCT LiquiColor Assay) were evaluated and compared to each other to choose the best method for routine use.
There is more and more interest in procalcitonin as a biomarker for sepsis due to its advantages against others conventional markers. Procalcitonin is a good marker for bacterial infection such as sepsis and that does not increase in case of viral infection. Furthermore, procalcitonin provides a fast diagnosis which is very important for sepsis patients.
The kits were compared on the basis of the repeatability, reproducibility and the trueness. Three concentration levels (negative, weakly positive and strongly positive) were measured ten times on the same day for the intra-run imprecision. For the inter-run imprecision, the three concentration levels were measured one time a day on ten different days. The intra-run and the inter-run of the methods have to meet the acceptation criterium of standard deviation <0,0375 ng/ml procalcitonin. Samples of sepsis patients, patients infected by influenza/RSV, patients on meropenem and intensive care patients were used for the trueness. The trueness of the methods was evaluated based on the absolute bias plot with an acceptation criterium of ± 0,075 ng/ml and on the passing-bablok with confidence intervals of 95%.
The repeatability and the reproducibility of Vidas Brahms PCT met the acceptation criterium for the three concentration levels. Only the negative and weakly positive concentration levels of Elecsys Brahms PCT met the criterium. For the PCT LiquiColor Assay, the weakly positive and strongly positive did not meet the criterium of the repeatability and the repeatability of the negative concentration level can not be measured because the results were below the lower limit of quantification. Therefore, no further research was being done for PCT LiquiColor. Vidas Brahms PCT and Elecsys Brahms PCT both did not meet the criterium for the trueness.
According to the results of the repeatability and reproducibility, it can be concluded that the Vidas Brahms PCT is better than the other two methods and suitable for use in the routine laboratory. However, the trueness of this method did not meet the criterium. The main reason for choosing the Vidas Brahms PCT is its lower price.
Abstract bachelorproef 2 2016-2017: Comparative study of the EGFR test on the IdyllaTM
Wegens confidentialiteit kan de samenvatting niet gepubliceerd worden.
Tryptase is an enzyme, made and stored in mast cells. The measurement of tryptase is a useful marker in the diagnosis of systemic mastocytosis, allergic reactions and anaphylaxis.
Tryptase can be measured with a Phadia system. These days AZ Groeninge sends the samples for measuring tryptase to UZ Leuven. But AZ Groeninge would like to investigate the possibility of determining tryptase in their own laboratory. So the purpose is to validate the tryptase assay on the Phadia 250 system in the laboratory of AZ Groeninge.
For the validation of the Phadia 250 system of AZ Groeninge, a few performance characteristics were evaluated: precision (reproducibility and repeatability), trueness, uncertainty of measurement, method comparison and measurement range. Also the stability of tryptase in serum was evaluated.
For the evaluation of the reproducibility and the trueness the tryptase level of the Tryptase Control and the Curve Control was measured on ten different days. The coefficient of variation (CV) and the relative bias (Brel) were calculated. The CV is used to evaluate the between-day reproducibility and the Brel to evaluate the trueness. The CV was lower than the proposed 10% and the Brel was situated between -10% and +10%.
Two patient samples, one with a high tryptase level and one with a low tryptase level, were used for the evaluation of the repeatability. The concentration of tryptase was measured ten times in the same run. The within-run precision was acceptable with a CV lower than 10%.
The uncertainty of measurement (Total Error (TE) = Brel + 1,65 * CV) was determined with the previous results. The TE of both controls was lower than the calculated error limit of 26,5%.
Since there was no reference method available, we compared results of 32 samples that were determined in UZ Leuven on a Phadia 1000 system. A Wilcoxon test showed a statistically significant bias. Passing-Bablok regression analysis showed a significant slope and a non-significant intercept. However, the difference was clinically acceptable according to the absolute difference plot between the two methods.
The manual of the Phadia 250 system states that the machine can measure tryptase levels between 1 and 200 µg/L. Calibrators were used as samples and the Brel was calculated. With a Brel between ±15% the measuring range between 1 and 200µg/L was confirmed.
Regarding stability tryptase should be measured within five days if a sample is stored in the refrigerator according to the manufacturer. Tryptase was measured on five new samples and then stored in the refrigerator. Tryptase was measured again after five and seven days. There was no statistically significant difference between the results from day one, five and seven. Thus samples can be stored for up to seven days in the refrigerator.
The conclusion is that the Phadia 250 system in AZ Groeninge can be used for the routine measurement of tryptase in serum. It showed acceptable performance characteristics regarding precision, trueness, measurement uncertainty, method comparison, measuring range and stability.
Abstract bachelorproef 2 2015-2016: Development of controls for immunohistochemical staining
Wegens confidentialiteit kan de samenvatting niet gepubliceerd worden
President Kennedylaan 4
Annelies De Bel